Literature DB >> 18665809

Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis.

Eric G Romanowski1, Francis S Mah, Regis P Kowalski, Kathleen A Yates, Y Jerold Gordon.   

Abstract

PURPOSE: The aim of this study was to determine whether a preservative (0.005% benzalkonium chloride [BAK]) enhances the antibacterial efficacy of an antibiotic (0.3% gatifloxacin, [GAT]) in vivo.
METHODS: Rabbits were inoculated intrastromally with GAT-resistant, methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis and then divided into four treatment groups: 0.3% GAT + 0.005% BAK; 0.3% GAT without BAK; vehicle including 0.005% BAK; and saline control. At 4 h postinoculation, topical treatment was initiated in both eyes every 15 min for 5 h. One (1) h after therapy, corneal colony counts were determined.
RESULTS: For S. aureus, duplicate experiments demonstrated that GAT + BAK and GAT without BAK significantly reduced colony counts, compared with BAK or saline (P < 0.05). Further, GAT + BAK significantly reduced colony counts, compared with GAT without BAK. BAK alone was equivalent to the saline control. For S. epidermidis, duplicate experiments demonstrated that GAT + BAK and GAT without BAK significantly reduced colony counts, compared with BAK or saline (P < 0.05). There were no differences between GAT + BAK and GAT without BAK for S. epidermidis.
CONCLUSIONS: For the first time, we demonstrated that a preservative (0.005% BAK) significantly enhanced the antibacterial efficacy of an antibiotic (0.3% GAT) in an experimental rabbit model of intrastromal keratitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18665809     DOI: 10.1089/jop.2008.0017

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  7 in total

1.  Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.

Authors:  Regis P Kowalski; Eric G Romanowski; Francis S Mah; Robert M Q Shanks; Y J Gordon
Journal:  Acta Ophthalmol       Date:  2010-04-23       Impact factor: 3.761

2.  [Morphological alterations induced by preservatives in eye drops].

Authors:  K K Huber-van der Velden; H Thieme; M Eichhorn
Journal:  Ophthalmologe       Date:  2012-11       Impact factor: 1.059

3.  The In Vitro Evaluation of Tigecycline and the In Vivo Evaluation of RPX-978 (0.5% Tigecycline) as an Ocular Antibiotic.

Authors:  Eric G Romanowski; Tyler A Kowalski; Katherine E O'Connor; Kathleen A Yates; Francis S Mah; Robert M Q Shanks; Regis P Kowalski
Journal:  J Ocul Pharmacol Ther       Date:  2015-11-06       Impact factor: 2.671

4.  Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis.

Authors:  Lorenzo J Cervantes; Francis S Mah
Journal:  Clin Ophthalmol       Date:  2011-04-18

5.  Methicillin resistance of Staphylococcus species among health care and nonhealth care workers undergoing cataract surgery.

Authors:  Randall Olson; Eric Donnenfeld; Frank A Bucci; Francis W Price; Michael Raizman; Kerry Solomon; Uday Devgan; William Trattler; Steven Dell; R Bruce Wallace; Michelle Callegan; Heather Brown; Peter J McDonnell; Taryn Conway; Rhett M Schiffman; David A Hollander
Journal:  Clin Ophthalmol       Date:  2010-12-10

Review 6.  Animal models of bacterial keratitis.

Authors:  Mary E Marquart
Journal:  J Biomed Biotechnol       Date:  2011-01-04

7.  Corneal alternations induced by topical application of benzalkonium chloride in rabbit.

Authors:  Wensheng Chen; Zhiyuan Li; Jiaoyue Hu; Zhenhao Zhang; Lelei Chen; Yongxiong Chen; Zuguo Liu
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.